Investment Analysts’ Weekly Ratings Updates for LENZ Therapeutics (LENZ)

A number of firms have modified their ratings and price targets on shares of LENZ Therapeutics (NASDAQ: LENZ) recently:

• 4/15/2024 – LENZ Therapeutics had its “outperform” rating reaffirmed by analysts at Leerink Partnrs.
• 4/15/2024 – LENZ Therapeutics is now covered by analysts at SVB Leerink LLC. They set an “outperform” rating and a $32.00 price target on the stock.
• 4/15/2024 – LENZ Therapeutics is now covered by analysts at William Blair. They set an “outperform” rating on the stock.
• 4/10/2024 – LENZ Therapeutics is now covered by analysts at Citigroup Inc.. They set a “buy” rating and a $34.00 price target on the stock.
• 3/27/2024 – LENZ Therapeutics is now covered by analysts at Piper Sandler. They set an “overweight” rating and a $28.00 price target on the stock.

LENZ Therapeutics Price Performance

NASDAQ:LENZ traded down $0.21 during trading on Thursday, reaching $15.65. The company’s stock had a trading volume of 64,088 shares, compared to its average volume of 61,363. The company has a market capitalization of $57.12 million, a PE ratio of -1.00 and a beta of 0.20. LENZ Therapeutics, Inc. has a 12 month low of $14.07 and a 12 month high of $29.82.

Insider Buying and Selling at LENZ Therapeutics

In other news, Director Ra Capital Management, L.P. acquired 998,009 shares of LENZ Therapeutics stock in a transaction dated Thursday, March 21st. The shares were purchased at an average cost of $15.03 per share, for a total transaction of $15,000,075.27. Following the transaction, the director now owns 3,319,339 shares of the company’s stock, valued at $49,889,665.17. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 38.40% of the company’s stock.

Institutional Trading of LENZ Therapeutics

An institutional investor recently bought a new position in LENZ Therapeutics stock. BML Capital Management LLC acquired a new stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ) in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 63,916 shares of the company’s stock, valued at approximately $1,427,000. LENZ Therapeutics comprises approximately 0.9% of BML Capital Management LLC’s investment portfolio, making the stock its 17th biggest position. BML Capital Management LLC owned 1.75% of LENZ Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 54.32% of the company’s stock.

LENZ Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.